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Sunday, November 1, 2015 
 
14:00 – 16:15  Conference Check-in (Claremont Ballroom) 
    
16:15 – 16:30  Welcome – Conference Chairs and ECI Liaison 
  
16:30 – 17:15  Keynote Lecture 1 
The deployment of continuous manufacturing approaches to improve network 
performance 
Alison Moore, Amgen, USA 
 
17:15 – 18:45  Workshops (2 in parallel) 
 
Workshop 1:  Business Case for Integrated Continuous Bioprocessing 
(Sponsored by Pall Life Sciences) 
(Napa Room) 
Chairs:  Suzanne Farid, University College London, United Kingdom 
    Christopher Hwang, Genzyme, a Sanofi company, USA 
 
 Workshop 3:  Standardization of Continuous Bioprocessing Terminology 
 (Sponsored by Lonza Biologics) 
 (Sonoma Room) 
Chairs:  Alois Jungbauer, University of Natural Resources and Life Sciences, Austria 
  Veena Warikoo, Genzyme, a Sanofi company, USA 
  
19:30 – 21:30  Dinner (Claremont Ballroom) 
 





• Technical Sessions will be held in Empire Ballroom. 
• Poster Sessions will be held in the Claremont Ballroom. 
• Workshops 1 and 2 will be in the Napa Room. Workshops 3 and 4 will be in the Sonoma Room. 
• The ECI office will be the Alumni Room. 
• The Lanai and Monterey rooms will be available during the week for ad hoc meetings. A sign up sheet will 
be available to reserve the rooms. 
• Meals on Monday, Tuesday and Wednesday will be in the Sonoma and Monterey Rooms. Breakfast on 
Thursday will be in the Empire Ballroom.  
• Audiotaping, videotaping and photography of presentations are prohibited. 
• Speakers – Please leave at least 5 minutes for questions and discussion. 
• Please do not smoke at any conference functions. 
• Turn your cellular telephones to vibrate or off during technical sessions. 
• After the conference, ECI will send an updated participant list to all participants.  Please check your listing 
now and if it needs updating, you may correct it at any time by logging into your ECI account.  
• Please do not smoke at any conference functions. 
• Please write your name in the front of this program booklet so it can be returned if misplaced. 
  
Monday, November 2, 2015 
 
07:30 – 09:00 Breakfast (Sonoma and Monterey Rooms) 
 
09:00 – 09:45 Keynote Lecture 2 
Introducing new technology in pharmaceutical manufacturing 
Janet Woodcock, CDER, FDA, USA 
 
09:45 – 10:15 Coffee / Networking Break 
 
 Session 1: Upstream Processing  
(Sponsored by Amgen) 
Chairs:  Paula Alves, IBET, Portugal 
Thierry Ziegler, Sanofi, France 
 
10:15 – 10:40 Delivering steady-state product quality with an intensified and integrated perfusion 
cell culture process 
   Jason Walther, Genzyme, a Sanofi company, USA 
 
10:40 – 11:05 Exometabolome characterization of high cell density culture perfusion and 
optimization of the cell specific perfusion rate 
   Veronique Chotteau, KTH, Sweden 
 
11:05 – 11:30 Development of a first generation perfusion process and medium for continuous 
processing based on existing fed-batch platform media 
   Henry Lin, Boehringer Ingelheim, USA 
 
11:30 – 11:55  Medium optimization case study for continuous upstream process 
   Alan Gilbert, Biogen, USA 
 
11:55 – 12:20  Upstream perfusion process: Back to the future 
   Jean-Marc Bielser, EMD Serono, Switzerland 
 
12:20 – 13:45 Lunch (Sonoma and Monterey Rooms) 
 
   Session 2: Downstream Processing  
(Sponsored by GE Healthcare) 
Chairs: Jens Vogel, Boehringer Ingelheim Pharma, USA 
    Dan Bracewell, University College London, United Kingdom 
 
13:45 – 14:10 Integration of continuous ethanol precipitation and flocculation into manufacturing 
of antibodies 
   Alois Jungbauer, University of Natural Resources and Life Sciences, Austria 
 
14:10 – 14:35  Towards continuous aqueous two-phase extraction (CATPE) 
   Andreas S. Bommarius, Georgia Institute of Technology, USA 
 
14:35 – 15:00  Considerations for an incubation chamber for continuous viral inactivation 
   Raquel Orozco, Boehringer Ingelheim, USA 
 
15:00 – 15:25 Robust design and operation of quasi-continuous adenovirus purification by two-
column, simulated moving-bed, size-exclusion chromatography 
   José P. B. Mota, Universidade Nova de Lisboa, Portugal 
 
15:25 – 15:50 Continuous downstream process or connected batch process: Which one makes 
most sense for Biogen? 
   John Pieracci, Biogen, USA 
Monday, November 2, 2015 (continued) 
 
15:50 – 16:20 Coffee / Networking Break 
 
Session 3: Clinical and Commercial Facility Design  
(Sponsored by Sartorius Stedim Biotech) 
Chairs: Thomas Daszkowski, Bayer Technology Services GmbH, Germany 
    Patrick Sheehy, Janssen, Ireland 
 
16:20 – 16:45 What is holding the industry back from implementing CBP (Continuous 
Bioprocessing) more broadly?  
   Morten Munk, NNE Pharmaplan, Denmark 
 
16:45 – 17:10 Evaluating facility design and capacity planning decisions for clinical and 
commercial supply with hybrid continuous processes 
   Suzanne S. Farid, University College London, United Kingdom 
 
17:10 – 17:35  What are the facility design requirements to fit biologics pipeline demands? 
   Thomas Sauer, Sanofi, Germany 
 
17:35 – 18:00 A biomanufacturing facility based on continuous processing and single use 
technology 
   Jorgen Magnus, Bayer Technology Services, Germany 
 
18:00 – 18:25  Impact of closed and continuous processing on biopharmaceutical facility layouts 
   Marc Pelletier, CRB, USA 
 
18:25 – 19:00 Coffee / Networking Break 
 
19:00 – 20:15 Poster Snapshot Session  
 Chairs: Haleh Ahmadian, Novo Nordisk, Denmark 
  Sa Ho, Pfizer Global R&D, USA 
  Chris Love, Massachusetts Institute of Technology, USA 
  Todd Przybycien, Carnegie Mellon University, USA 
  
 Monitoring intracellular component pools to identify steady state in mammalian 
cell perfusion culture (Poster 21) 
Daniel Karst, ETH Zurich, Switzerland 
 
Designing a microbial cultivation platform for continuous biopharmaceutical 
production (Poster 37) 
Nicholas J. Mozdzierz, Massachusetts Institute of Technology, USA 
 
Continuous production of viral vaccines with a two-stage bioreactor system  
(Poster 32) 
Felipe Tapia, Max Planck Institute Magdeburg, Germany 
 
Mathematical modeling of a bioreactor producing Epo-hr operating in perfusion 
mode (Poster 30) 
Osmán Fernández, Center of Molecular Immunology, Cuba 
 
Alternating flow filtration as an alternative to internal spin filter based perfusion 
process: Impact on productivity and product quality (Poster 45) 




Monday, November 2, 2015 (continued) 
 
Comparison of bioreactor systems operated at high bacterial cell density for the 
production of lactic acid: Batch – CSTR – CSTR cascade – Tubular reactor  
(Poster 27) 
Ulrich Kulozik, Technische Universität München, Germany 
 
Continuous countercurrent tangential chromatography for purification of high 
value therapeutic proteins (Poster 19) 
Andrew Zydney, The Pennsylvania State University, USA 
 
Evaluation of a continuous chromatography process through process modeling 
and resin characterization (Poster 26 ) 
Ketki Behere, University of Mass Lowell, USA 
 
Design of a continuous precipitation operation for protein capture (Poster 41) 
Todd Przybycien, Carnegie Mellon University, USA 
 
Biopharmaceutical capacity planning for batch and semi-continuous bioprocesses 
under various strategic criteria (Poster 42) 
Cyrus Siganporia, University College London, United Kingdom 
 
Optical enzymatic sensors for continuous monitoring of bioreactors (Poster 5) 
Kenneth F. Reardon, Colorado State University, USA 
 
Advanced computational tools to enhance continuous monoclonal antibody 
production (Poster 4) 
Maria M. Papathanasiou, Imperial College London, United Kingdom 
 
Spectral deconvolution of chromatograms without offline analytics (Poster 1) 
Matthias Rüdt, Karlsruhe Institute of Technology, Germany 
 
20:15 – 21:45 Dinner (Sonoma and Monterey Rooms) 
 






Tuesday, November 3, 2015 
 
07:30 – 08:30 Breakfast (Sonoma and Monterey Rooms) 
 
   Session 4: Integrated Continuous Processing  
(Sponsored by Pfizer) 
   Chairs: Nigel Titchener-Hooker, University College London, United Kingdom  
    Jon Coffman, Boehringer Ingelheim Pharma, USA 
 
08:30 – 08:55 Innovations in bioreactor operational modes – Hybrid semi-continuous processes 
to push beyond the limits of conventional fed-batch cultures 
   Gregory Hiller, Pfizer, Inc., USA 
 
08:55 – 09:20 Development of functionally closed downstream operations for continuous 
biomanufacturing of recombinant therapeutic proteins 
   Rohan Patil, Genzyme, a Sanofi company, USA 
 
09:20 – 09:45  Integrated continuous bioprocessing – opportunities and challenges 
   Mats Åkesson & Peter Tiainen, Novo Nordisk A/S, Denmark 
 
09:45 – 10:15 Coffee / Networking Break 
 
10:15 – 10:40  Design and control of chromatography step in an integrated column sequence 
   Bernt Nilsson, Lund University, Sweden 
 
10:40 – 11:05 Integrated continuous processing for the manufacture of monoclonal antibodies 
   Massimo Morbidelli, ETH Zurich, Switzerland 
 
11:05 – 11:30 Continuous culture and downstream processing of algae with recycle: An 
integrated large-scale approach for production of renewable crude oil 
   Matt Croughan, Keck Graduate Institute, USA 
 
11:30 – 12:00 Coffee / Networking Break 
 
12:00 – 12:45 Keynote Lecture 3 
 Continuous beer production methods: A review of chances and risks 
Konrad Mueller-Auffermann, Krones AG, Germany 
 
12:45 – 21:00 Boxed Lunch & Free Time / Excursion (early dinner on your own before returning to 
hotel)  
 Boxed lunches can be picked up outside the hotel main entrance by the valet/shuttle 
area. 
 
21:00 – 23:00 Poster Session with dessert and Social Hour 
   Chairs: Haleh Ahmadian, Novo Nordisk, Denmark 
    Sa Ho, Pfizer Global R&D, USA 
    Chris Love, Massachusetts Institute of Technology, USA 




Wednesday, November 4, 2015 
 
07:00 – 08:30 Breakfast (Sonoma and Monterey Rooms) 
  
09:00 – 10:30 Workshops (2 in parallel) 
 
 Workshop 2: Strategic Considerations for Technology Development in USP & DSP  
(Sponsored by Biomarin) 
(Napa Room) 
Chairs: Art Hewig, Amgen, USA 
    Jim Michaels, BioMarin, USA  
 
 Workshop 4: Scale-up/Scale-down and QbD Challenges 
 (Sonoma Room) 
Chairs:  Ajoy Velayudhan, University College London, United Kingdom 
  Chun Zhang, Shire, USA 
 
10:30 – 11:00 Coffee / Networking Break 
 
 Session 5:  PAT, Monitoring and Control  
(Sponsored by LEWA Process Technologies) 
Chairs: Marcel Ottens, Delft University, The Netherlands 
John Pieracci, Biogen Idec, USA 
 
11:00 – 11:25 Monitoring and control of reproducibility in quasi-continuous integrated 
production processes of Active Pharmaceutical Ingredients 
   Reiner Luttmann, Hamburg University of Applied Sciences, Germany 
 
11:25 – 11:50 Protein Refinery Operations Lab (PRO Lab): A sandbox for continuous protein 
production & advanced process control 
   Mark Brower, Merck & Co., Inc., USA 
 
11:50 – 12:15  The use of dynamic control in periodic counter current chromatography 
   Hans Blom, GE Healthcare, Sweden 
 
12:15 – 12:40 Leveraging large data sets in continuous chromatography applications: Monitoring 
critical process parameters using MVDA 
   Engin Ayturk, Pall Corporation, The Netherlands 
 
12:40 – 13:05 PAT concepts for chromatography: Real-time monitoring, real-time control, and 
cause of error diagnostics 
   Nina Brestrich, Karlsruhe Institute of Technology, Germany 
 
13:05 – 14:45 Lunch (Sonoma and Monterey Rooms) 
 
 Session 6:  Vaccine and Cell Therapy Processing  
(Sponsored by the Bill & Melinda Gates Foundation) 
 Chairs: James Piret, University of British Columbia, Canada 
Barry Buckland, University College London, United Kingdom 
 
14:45 – 15:05  Dynamic oncolytic measles virus production 
Tanja A. Grein, Institute of Bioprocess Engineering and Pharmaceutical Technology, 
Germany 
 
15:05 – 15:30 How continuous-like processes improve affordability for viral vaccines - Example 
of LAIV 
   Jose Castillo, Univercells, Belgium 
Wednesday, November 4, 2015 (continued) 
 
15:30 – 15:55  Small-scale platform for rapid on-demand manufacturing of recombinant proteins 
   J. Christopher Love, Koch Institute at MIT, USA 
 
15:55 – 16:20 Exploring continuous and integrated strategies for the up- and downstream 
processing of human mesenchymal stem cells 
   Paula M. Alves, iBET/ITQB-UNL, Portugal 
  
16:20 –16:50 Coffee / Networking Break 
 
 Session 7:  Regulatory Considerations  
(Sponsored by Sanofi) 
   Chairs: Mark Heintzelman, Genzyme, a Sanofi company, USA 
  Kurt Brorson, Food and Drug Administration, USA 
 
16:50 – 17:15  CDER's emerging technology team 
   Kurt Brorson, CDER, FDA, USA 
 
17:15 – 17:40  Quality systems for continuous manufacturing 
   Ron Branning, RBC LLC, Quality Systems Consulting, USA 
 
17:40 – 18:05  Regulatory challenges of continuous biomanufacturing 
   Andrew N. Papas, NSF Health Sciences Pharma Biotech Consulting, USA 
 
18:05 – 18:30  A regulatory perspective on continuous perfusion production of rFVIII 
   Robert Kozak, Bayer HealthCare, USA 
 
18:30 –19:00  Coffee / Networking Break 
 
19:00 – 19:45 Keynote Lecture 4 
 Transforming the present into the future with uncertainty and imprecision 
Charles Cooney, Massachusetts Institute of Technology, USA 
 
20:30 – 22:30 Conference Banquet and Poster Awards (Sonoma and Monterey Rooms) 
 





Thursday, November 5, 2015 
 






Workshop 1:  Business Case for Integrated Continuous Bioprocessing 
(Sponsored by Pall Life Sciences) 
Chairs:  Suzanne Farid, University College London, United Kingdom 
 Christopher Hwang, Genzyme, a Sanofi company, USA 
 
There is a growing interest in exploring and developing integrated continuous bioprocesses (ICB) for the 
production of biologics as evident by a significant increase in the number of companies and academic 
labs working on it over the past few years.  Among the many strategic advantages of ICB, many cite 
lowering costs (capital expenditure and/or operating expenses), flexible capacity management, 
operational flexibility, minimizing tech transfer risks, and enhanced product quality as primary drivers for 
ICB. 
 
In this workshop, we would like to explore these and other business drivers for implementing ICB.  We will 
be tapping into your experiences on these two core themes and insights to answer questions such as: 
 
Theme 1: Drivers for integrated continuous bioprocessing 
 
1. What business and operational drivers are important to you and why?  
(e.g., COG, cost of development, overall lifecycle profitability, development timeline, risk, flexibility) 
 
2. How would you rank these drivers for ICB implementation for early phase versus commercial 
manufacture? How would this influence your recommendation? 
 
3. How do you envisage ICB impacting development timeline drivers (process development, tech 
transfer, process characterization, PV/PPQ batches)? 
 
4. What kind of decision-making tools do you use to measure the impact of ICB on key business and 
operational drivers? 
 
Theme 2: Developing a business case for integrated continuous bioprocessing 
 
1. How do you develop a business case that captures the key drivers for ICB so as to convince senior 
management?  
 
2. What challenges have you faced in convincing senior management to adopt ICB? Can you share 
lessons learnt on building a business case? 
 
3. How do you capture intangible benefits such as “flexibility” when operating multiproduct facilities into 
your business case?  
 
4. How might a business case for ICB differ between a small and a large company? 
 
Our goal is to facilitate a lively and interactive discussion where we encourage open dialogue and sharing 
of experiences from all participants. Please feel free to forward comments to us for additional suggestions 
and prioritization of topics for the group to tackle ahead of the meeting. 
 
  
Workshop 2: Strategic Considerations for Technology Development in USP and DSP  
(Sponsored by Biomarin) 
Chairs: Art Hewig, Amgen, USA 
 Jim Michaels, BioMarin, USA 
 
Implementation of continuous manufacturing in the biopharmaceutical industry will require the 
development of key technologies in upstream and downstream processing. One important aspect is 
defining strategic goals to determine which key enabling technologies to invest in. Without a clear 
strategy it is difficult to refine technology development efforts and this can result in diluted efforts and 
limited progress. Two examples of key strategic considerations include facility constraints (footprint, 
capital investment, liquid handling, staffing/automation) and portfolio mix (predicted mass needs per 
program, number of programs, new modalities). These types of strategic considerations help to focus 
efforts put into specific mass output, bioreactor perfusion rates, continuous purification adoption, as well 
as the level of process and automation complexity employed. The aim of this workshop is to showcase, 
discuss, and explore how specific technology development efforts in upstream and downstream can help 




Workshop 3:  Standardization of Continuous Bioprocessing Terminology 
(Sponsored by Lonza Biologics) 
Chairs: Alois Jungbauer, University of Natural Resources and Life Sciences, Austria 
 Veena Warikoo, Genzyme, a Sanofi company, USA 
 
Those who have started to have a closer look on integrated continuous biomanufacturing have pretty 
soon come to the question “how continuous is continuous?” To establish the technology in industry we 
need to communicate with different groups and stakeholders. Industry must file license applications to 
health agencies, vendors must sell products and processes to industry and academia must communicate 
new research and train new scientists and engineers. There is definitely a need to define terminology in 
this field. We will start from the very basic concepts of real continuous, pseudo-continuous, quasi-
continuous to a more sophisticated engineering terminology including definitions of reactor types and 
states of reactions in continuous bioprocessing. In this workshop these terms will be openly discussed 




Workshop 4:  Scale-up/Scale-down and QbD Challenges  
Chairs:  Ajoy Velayudhan, University College London, United Kingdom  
 Chun Zhang, Shire, USA 
 
Scalability is a critical issue for conventional batch bioprocessing, and considerable work has been done 
to evaluate scale-up and scale-down for various unit operations. Similar studies are needed for 
continuous unit-operations. This session will focus on experimental and theoretical approaches to 
scalability of single steps and sequences of steps relevant to bioprocessing. Since control of continuous 
steps is particularly important, contributions are also sought on the related issue of Quality by Design. 
Evaluation of critical process parameters for continuous steps is of particular interest. 
 
Poster Presentations  
 
 
Analytics & Control 
 
1.  Spectral deconvolution of chromatograms without offline analytics 
Matthias Rüdt, Karlsruhe Institut für Technologie, Germany 
 
2.  PAT concepts for the process monitoring and control of continuous biomanufacturing 
Eike Zimmermann, Boehringer-Ingelheim, USA 
 
3.  Inline spiking for viral clearance validation of continuous processes 
Herb Lutz, Emd Millipore, USA 
 
4.  Advanced computational tools to enhance continuous monoclonal antibody production 
Maria M. Papathanasiou, Imperial College London, United Kingdom 
 
5.  Optical enzymatic sensors for continuous monitoring of bioreactors 
Kenneth F. Reardon, Colorado State University, USA 
 
6.  Optimal control of a continuous bioreactor for maximized beta-carotene production 
M. Nazmul Karim, Texas A&M University, USA 
 
7.  Strategy for scaling semi-continuous downstream and integration of process analytical 
tools for monoclonal antibody toxicology 





8.  Continuous production of proteins: Integration of polishing using MCSGP 
Fabian Steinebach, ETH Zurich, Switzerland 
 
9.  Process time and cost savings achieved through automation and islands of integration in 
existing facilities. 
Lynne Frick, Pall Life Sciences, United Kingdom 
 
10.  Tools for process intensification upstream and continuous processing downstream 
James Rusche, Repligen Corporation, USA 
 
11.  Integrated solutions for continuous processing in Mobius® bioreactor systems 
Andrew Clutterbuck, Merck Millipore, France 
 
12.  Laboratory scale continuous linear purification as a development tool for recombinant 
blood protein processing, using chromatographic resins and membranes 
Rimenys J. Carvalho, Federal University of Rio De Janeiro, Brazil 
 
13.  Integrated and single use continuous manufacturing 
Colin Jaques, Lonza, United Kingdom 
 
14.  Enabling technologies for integrated / continuous downstream processing of biologics 






15.  Design criteria and requirements for development of perfusion media 
Jochen B. Sieck, Merck KGaA, Germany 
 
16.  GlycoExpress: A toolbox for the high yield production of glycooptimized fully human 
biopharmaceuticals in perfusion bioreactors at different scales 
Steffen Kreye, Glycotope GmbH, Germany 
 
17.  Genomics based methodology of cell-culture media formulation for improved bio-
therapeutic productivity and quality consistency 
Hemlata Bhatia, University of Massachusetts, Lowell, USA 
 
18.  Novel compact cell settlers for continuous perfusion bioreactor cultures of microbial (and 
mammalian) cells 
Dhinakar Kompala, Sudhin Biopharma Company, USA 
 
19.  Continuous countercurrent tangential chromatography for purification of high value 
therapeutic proteins 
Andrew Zydney, The Pennsylvania State University, USA 
 
20.  Factors affecting the productivity of 4-Column Periodic Counter Current Chromatography 
(4C-PCC) 
Laura Fagan, Actavis Biologics Ltd., United Kingdom 
 
21.  Monitoring intracellular component pools to identify steady state in mammalian cell 
perfusion culture 
Daniel Karst, ETH Zurich, Switzerland 
 
22.  Simple method transfer from batch to continuous chromatography process to fit 
parameters to business needs 
Rene Gantier, Pall Life Sciences, USA 
 
23.  EcoPrime twin – Scale-up of CaptureSMB to the process scale 
Kathleen Mihlbachler, LEWA Process Technologies, USA 
 
24.  A novel plant cell culture platform for semicontinous production of recombinant proteins: 
Butyrylcholinesterase as a case study 
Karen A. McDonald, University of California, Davis, USA 
 
25.  Case study: Optimisation of a stabilised large scale atf perfusion process 
Jarno Robin, Novo Nordisk, Denmark 
 
26.  Evaluation of a continuous chromatography process through process modeling and resin 
characterization 
Ketki Behere, University of Mass Lowell, USA 
 
27.  Comparison of bioreactor systems operated at high bacterial cell density for the 
production of lactic acid: Batch – CSTR – CSTR cascade – Tubular reactor 
Ulrich Kulozik, Technische Universität München, Germany 
 
28.  Scale up and implementation of a high density long-term perfusion suspension cell 
culture in a 250L single use bioreactor 
Weichang Zhou, WuXi AppTec Co., Ltd, China 
 
 
29.  BioSC® predict simulation software: FLexibility and optimization of your multi-column 
process 
Fabien Rousset, Novasep, France 
 
30.  Mathematical modeling of a bioreactor producing Epo-hr operating in perfusion mode 
Osmán Fernández, Center of Molecular Immunology, Cuba 
 
31.  Efficient approaches for perfusion medium development 
Andreas Castan, GE Healthcare Life Sciences, Sweden 
 
32.  Continuous production of viral vaccines with a two-stage bioreactor system 
Felipe Tapia, Max Planck Institute Magdeburg, Germany 
 
33.  Continuous downstream processing of a monoclonal antibody using Periodic Counter 
Current Chromatography (PCC) and Straight Through Processing (STP) 
Hans Blom, GE Healthcare, Sweden 
 
34.  Bioprocess economics and optimization of continuous and pre-packed disposable 
chromatography 
Richard Allmendinger, University College London, United Kingdom 
 
35.  Modeling perfusion at small scale using ambr15TM 
Delia Lyons, SAFC, USA 
 
36.  Evaluation of novel CEX resin for continous processing of MAb purification 
Takuya Muramoto, Takeda Pharmaceutical Company Limited, Japan 
 
37.  Designing a microbial cultivation platform for continuous biopharmaceutical production 
Nicholas J. Mozdzierz, Massachusetts Institute of Technology, USA 
 
38.  Continuous purification of hepatitis C virus-like particles by multi-column 
chromatography 
José Mota, FCT-UNL, Portugal 
 
39.  BHK cells physiological response to spin-filter stress condition 
Aldo Tonso, University of Sao Paulo, Brazil 
 
40.  mAb product consistency achieved in long duration microfiltration-based CHO perfusion 
process 
Douglas Rank, EMD Millipore, USA 
 
41.  Design of a continuous precipitation operation for protein capture 
Todd Przybycien, Carnegie Mellon University, USA 
 
42.  Biopharmaceutical capacity planning for batch and semi-continuous bioprocesses under 
various strategic criteria 
Cyrus Siganporia, University College London, United Kingdom 
 
43.  Salt-tolerant cation exchange HD-Sb hydrogel membrane: mAb purification performance 
in flowthrough mode 
Annabel Shang, Natrix Separations Inc., Canada 
 
44.  Toward complete continuity in antibody biomanufacture: Multi-column continuous 
chromatography for Protein A capture and mixed mode hydroxyapatite polishing 
Anthony C. Grabski, Semba Biosciences, Inc., USA 
 
45.  Alternating flow filtration as an alternative to internal spin filter based perfusion process: 
Impact on productivity and product quality 
Guillermina Forno, Universidad Nacional Del Litoral, Argentina 
 
46.  Pilot scale hybrid fed batch and continuous processing of biologics 
Dave Sullivan, Pfizer, USA 
 
47.  From fed-batch to perfusion: Productivity and quality considerations for a late-stage 
program 
Sen Xu, Merck Research Laboratories, USA 
 
48.  Continuous culture in the age of single-use 
Melisa Carpio, Sartorius Stedim Biotech, Germany 
 
 
